Reagent Mixing in an Automated Assay Workflow: Using Data to Make Decisions
Date: Wednesday, May 26, 2021
Time: 18:00 PM (GMT)
Artel invites you to a special webinar featuring guest speaker: Dr. Nathaniel Hentz
Mixing steps within and automated assay protocol are often taken for granted. Compounding the issue is the transfer from manual to automated methods. When developing an assay manually, we “just know” how to mix it and often change our technique on the fly. However, translating this to an automation system is not trivial. Most commonly scientists rely on simple diffusion, a cursory agitation, or a default mixing step to do the job, which can work for aqueous based liquids. The more problematic mixing steps are those that involve liquids of different fluid properties, especially prominent in genomics workflows. By measuring the effect of mixing using Artel technology, the process can be optimised before incorporating the biology assay components. This saves time and headaches when developing or transferring the automated method. This webinar will present a basic overview of the mixing process and the importance within an assay. We will also briefly describe how to use Artel MVS Multichannel Verification System to measure and optimise your mixing step.
What you will learn:
- Why mixing is so critical to success in developing and automated assay
- The different mixing modes available to scientists
- How to employ Artel MVS Multichannel Verification System to measure effectiveness of automated assay mixing protocols
Dr. Nathaniel Hentz
Dr. Nathaniel Hentz is currently Director, Scientific Market Development at Artel. Prior to that, Dr. Hentz served as Assistant Director of the BTEC Analytical Lab at North Carolina State University for almost 11 years. In that role, he taught both undergraduate and graduate level courses as well as industry short courses focused on biopharmaceutical assay development and validation. Dr. Hentz’s tenure in the HTS industry includes nearly two years supporting the automated screening systems within the Lead Discovery group at Bristol-Myers Squibb in Connecticut and seven years developing screens at Eli Lilly RTP Laboratories in North Carolina.